JAK2 抗体 (AA 745-955)
-
- 抗原 See all JAK2 抗体
- JAK2 (Janus Kinase 2 (JAK2))
-
抗原表位
- AA 745-955
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This JAK2 antibody is un-conjugated
-
应用范围
- Immunohistochemistry (IHC), ELISA, Flow Cytometry (FACS)
- 原理
- JAK2 Antibody
- 纯化方法
- Purified antibody
- 免疫原
- Purified recombinant fragment of human JAK2 (AA: 745-955) expressed in E. Coli.
- 克隆位点
- 5C12C9
- 亚型
- IgG1
- Top Product
- Discover our top product JAK2 Primary Antibody
-
-
- 应用备注
-
ELISA: 1/10000
FCM: 1/200 - 1/400
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 缓冲液
- Purified antibody in PBS with 0.05 % sodium azide.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- 4 °C,-20 °C
- 储存方法
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
-
- 抗原
- JAK2 (Janus Kinase 2 (JAK2))
- 别名
- JAK2 (JAK2 产品)
- 别名
- JAK2bCA antibody, jak2 antibody, JTK10 antibody, THCYT3 antibody, AI504024 antibody, C81284 antibody, Fd17 antibody, JAK-2 antibody, Janus kinase 2b antibody, Janus kinase 2 antibody, jak2b antibody, JAK2 antibody, Jak2 antibody
- 背景
-
Description: This gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis.
Aliases: JTK10, THCYT3
- 分子量
- 130.7kDa
- 基因ID
- 3717
- HGNC
- 3717
- UniProt
- O60674
- 途径
- JAK/STAT Signaling, RTK signaling, Interferon-gamma Pathway, Positive Regulation of Peptide Hormone Secretion, Intracellular Steroid Hormone Receptor Signaling Pathway, Response to Growth Hormone Stimulus, Positive Regulation of Endopeptidase Activity, Protein targeting to Nucleus, CXCR4-mediated Signaling Events, Platelet-derived growth Factor Receptor Signaling, Unfolded Protein Response
-